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Abstract
Background: The prevalence of infections by Mycobacterium tuberculosis and non-tuberculous
Mycobacterium species in the HIV-infected patient population in Colombia was uncertain despite
some pilot studies. We determined the frequency of isolation of Mycobacterium tuberculosis and of
non-tuberculous Mycobacterium species in diverse body fluids of HIV-infected patients in Bogota,
Colombia.
Methods: Patients who attended the three major HIV/AIDS healthcare centres in Bogota were
prospectively studied over a six month period. A total of 286 patients were enrolled, 20% of them
were hospitalized at some point during the study. Sixty four percent (64%) were classified as stage
C, 25% as stage B, and 11% as stage A (CDC staging system, 1993). A total of 1,622 clinical samples
(mostly paired samples of blood, sputum, stool, and urine) were processed for acid-fast bacilli
(AFB) stain and culture.
Results: Overall 43 of 1,622 cultures (2.6%) were positive for mycobacteria. Twenty-two sputum
samples were positive. Four patients were diagnosed with M. tuberculosis (1.4%). All isolates of M.
tuberculosis were sensitive to common anti-tuberculous drugs. M. avium was isolated in thirteen
patients (4.5%), but only in three of them the cultures originated from blood. The other isolates
were obtained from stool, urine or sputum samples. In three cases, direct AFB smears of blood
were positive. Two patients presented simultaneously with M. tuberculosis and M. avium.
Conclusions: Non-tuberculous Mycobacterium infections are frequent in HIV infected patients in
Bogota. The diagnostic sensitivity for infection with tuberculous and non-tuberculous mycobacteria
can be increased when diverse body fluids are processed from each patient.
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Background
Mycobacterium infections are frequent opportunistic
pathogens associated with the acquired immunodefi-
ciency syndrome (AIDS). Its relative virulence and po-
tential for person-to-person transmission distinguishes
Mycobacterium tuberculosis. Persons infected with the
human immunodeficiency virus (HIV) are particularly
susceptible to tuberculosis, either by the reactivation of
latent infection or by a primary infection with rapid pro-
gression to active disease [1–4]. The annual incidence
rate of tuberculosis in Colombia during 1998 was 19.6
per 100,000 persons [5], but rates 1,000-fold higher
have been reported in some HIV-seropositive popula-
tions [6–14]. In addition, disseminated infections with
Mycobacterium avium complex are increasingly com-
mon in advanced human immunodeficiency virus (HIV)
disease and cause substantial morbidity [15,16]. Persons
with HIV infection and CD4 lymphocyte counts less than
100 cells/mm3 have a probability of 10% to 20% per year
of developing M. avium complex disease or bacteremia
[17,18]. Bacteremia involving M. avium complex produc-
es a wide array of clinical signs and symptoms, including
wasting, fever, and night sweats, and is associated with
decreased survival [17–20]. The recovery of mycobacte-
ria in blood cultures can help to discover bacteremia that
frequently goes unrecognized. We undertook a prospec-
tive survey in three AIDS health care units in Bogota, Co-
lombia, in order to determine the prevalence of
Mycobacterium species in HIV-infected patients and to
evaluate the diagnostic value of different types of body
fluids to detect the presence of mycobacteria.
Methods
Patients and study design
This study was a multicentric prospective study of the
frequency of Mycobacterium infections in persons in-
fected with HIV. The study was conducted in three major
AIDS health care programs of Bogota ("Hospital Univer-
sitario San Juan de Dios", "Hospital Regional Simon
Bolívar" and "Centro Atención Básica Chapinero del Se-
guro Social"). From October 1999 to March 2000, a total
of 289 HIV-seropositive patients were recruited. Most of
the participants met the definition of AIDS, or were in
clinical stage C (CDC, 1993). The institutional review
board at each site approved the study, and each partici-
pant gave written informed consent.
Specimen collection and culture media
For all patients blood, urine, stool and sputum samples
were collected. In brief, 5 to 8 mL of blood was obtained
in previously labeled Vacutainer™ tubes containing 1.7
mL of heparin as anticoagulant. All patients attempts
were made to collect two paired blood cultures samples
(n = 648), 2 urine cultures (n = 497), 2 stool cultures (n
= 374) and 2 sputum samples (n = 101). In one patient a
sample of ascitic fluid, and in other case cerebrospinal
fluid (CSF) were obtained. Bacteriologic methods were
used as previously described [21,22]. Briefly, blood sam-
ples were centrifuged 15 min at 2,000 g and leukocytes
recovered by standard methods with Ficoll-Hypaque
(Pharmacia Fine Chemicals, Piscataway, NJ) and then
mixed with a lysing solution that contained 0.45% sodi-
um deoxycholate. After manual mixing, tubes were cen-
trifuged at 3,500 g for 30 minutes in a refrigerated
centrifuge at 4,000 g and the supernatant was discarded.
The pellet was resuspended, and 0.2% bovine albumin
was added to yield a final volume of 2.5 mL.
One gr of stool samples was placed in 5 ml of albumin
Dubos media and mixed in Vortex™ for 2 min, then in-
cubated at room temperature overnight. Afterwards,
equal volumes of a solution of 2% NaOH were mixed in
Vortex™ for 2 min and incubated at room temperature
in continuos mixing for 15 min. Distilled water was add-
ed to complete 50 ml and the mixture was centrifuged at
6,000 g for 30 min. One drop of phenol red was added to
the pellet and then neutralized with 2 drops of HCl 2 N.
The pellet was resuspended in 2 ml of saline solution,
mixed and finally 0.2 ml used for culture.
Urine samples were mixed in a ratio of 3:1 with a solution
of 20% Na3PO4.12H2O. The mixture was incubated at
room temperature for 2 h and then centrifuged at 6,000
g for 30 min. The pellet was used for culture after being
decontaminated by Ogawa-Kudoh method. Briefly, ster-
ile slabs were placed in a solution of 4% NaOH during 1
or 2 min and then used to culture samples.
Sputum was mixed in equal volume with a solution of 4%
Na3PO4.12H2O, incubated at room temperature during 2
h and centrifuged at 6,000 g for 30 min. The pellet was
decontaminated by the Ogawa-Kudoh method, as de-
scribed above, and used for culture. The same procedure
was used for the ascitic fluid and CSF samples.
All samples were placed in 2 tubes with a biphasic medi-
um: a solid phase Ogawa-Kudoh with iron citrate and a
liquid phase of Sauton Twen albumin modified medium
and 2 tubes with Stonebrink-Giraldo medium. Readings
were made after day 6 and at 2, 4, 6, 8, 12 and 16 week. A
positive culture was identified following the criteria of
the Centers for Prevention and Disease Control (CDC)
[22]. Resistance assay was applied at all Mycobacterium
tuberculosis isolates using the proportion method for
streptomycin (S), isoniazide (H), thioacetazone (Tb),
ethambutol (E) and rifampicin (R).
All samples were stained and examined for AFB after
centrifugation.BMC Infectious Diseases 2001, 1:21 http://www.biomedcentral.com/1471-2334/1/21
Statistical analysis
Statistical significance for comparison of rates was deter-
mined by an exact test when sample sizes were insuffi-
cient and by an asymptotic test when sizes were
sufficient. All tests were two-sided, and a P value of 0.05
was considered significant. Exact 95% confidence inter-
vals (CI) were calculated for rates by assuming the nu-
merator to be a Poisson variable [23] and for rate ratios
using a modified binomial model [24]. Adjusted rate ra-
tios for comparisons among groups defined by demo-
graphic variables were calculated by using a Mantel-
Haenszel type estimator for incidence-rate data with ap-
proximate 95% confidence limits based on the tests [23].
Results
Demographic characteristics
In total, 286 patients were studied, 251 (87.8 %) were
men, and 35 (12.2%) were women. The men:women ratio
was 7:1. The age range was 3 to 78 years with a median of
35 years (Table 1). Ten patients (3%) were from "Hospi-
tal San Juan de Dios"; one-hundred thirty nine patients
(49%) were from "Hospital Simón Bolívar" and one hun-
dred thirty seven patients (48%) were from the "Instituto
de Seguro Social". Fifty-eight patients were hospitalized
at the time of enrollment (20%), and two hundred twenty
eight patients (80%) were enrolled at an outpatient clin-
ic. One hundred ninety five patients (68.5%) were in
treatment with antiretroviral medication. Sexual prefer-
ences were informed in 269 (94%) patients as follows: in
males, ninety (33.4%) were homosexual, eighty-six
(31.9%) were bisexual and sixty-one (22.7%) were heter-
osexual. Of the women, twenty-nine (90.6%) were heter-
osexual and three (9.4%) were bisexual. CDC staging in
these patients is shown in Table 1. Viral load was ob-
tained in 180 patients and results varied in a range be-
tween less than 50 and 13 millions copies/mL. The
median of viral load was 23,420 copies/mL.
The symptoms most frequently complaint of at the time
of initial enrollment were headaches (48%), loss of
weight (43%), and mental status changes (38%). The fre-
quency of each symptom is showed in Figure 1. 29% pa-
tients complaint of respiratory symptoms. 13% patients
had a history of diagnosis of tuberculosis, and 12% gave
a history of previous treatment with antituberculous
drugs.
Mycobacterium infection
Overall, sixteen of 286 patients (5.6%) were positive for
any Mycobacterium species by acid fast staining or cul-
ture of any of their samples. In these sixteen cases, fif-
teen (94%) were positive by culture, and one patient was
detected only by acid fast bacilli staining (6%). Fourteen
patients (87.5%) were men and two (12.5%) were wom-
en. M. tuberculosis was identified in four cases (1.4%).
M. avium was isolated in thirteen patients (4.2%). Two
patients presented simultaneous infection by M. tuber-
culosis and M. avium.
Tuberculosis was diagnosed in its pulmonary form in two
cases, and in another two patients as extrapulmonary. In
the patients with pulmonary tuberculosis, the AFB smear
of the sputum was positive in one case, and in another
Figure 1
Frequency of clinical symptoms
Table 1: Demographic characteristics of patients
Distribution by center n %
Hospital San Juan de Dios 10
Male 99 0
Women 11 0
Hospital Simon Bolívar 139
Male 128 95
Women 21 15
Seguro Social 137
Male 124 90
Women 13 10
Age groups
0 – 15 10 . 3 5
16 – 25 38 13.3
26 – 45 211 73.8
46 – 65 35 12.2
66 – 78 10 . 3 5
1993 CDC stages
A 31 11
B 69 24
C 186 65BMC Infectious Diseases 2001, 1:21 http://www.biomedcentral.com/1471-2334/1/21
case the AFB smear was positive in his stool sample. Cul-
ture of stool samples was positive in both cases of pulmo-
nary and in one case of extrapulmonary tuberculosis. M.
tuberculosis was detected in different samples of body
fluids as well: in sputum, urine, stool samples, and in as-
citic fluid (Table 2). All isolates of M. tuberculosis were
sensitive to the drugs assayed: streptomycin (S), isoni-
azide (H), thioacetazone (Th), ethambutol (E) and ri-
fampicin (R).
The only species identified as non-tuberculous mycobac-
teria was M. avium which was detected in 13 patients
(4.2%). Two patients had coinfection by M. tuberculosis
and M. avium in their sputum culture. One patient was
positive only for acid fast bacilli staining in two stool
samples but no growth was observed in culture tubes af-
ter 16 weeks of incubation. Interestingly, in three pa-
tients the direct AFB staining in blood was positive, and
M. avium was later identified in these blood cultures
(Table 3). M. avium was also detected in other clinical
samples: urine, stool and sputum (Table 4).
The percent of positive AFB smears and cultures was
greater in samples of sputum followed by the samples of
stool (Table 5). Samples of urine and stool were valuable
to identify most of patients with a M. avium infection,
only three patients infected by M. avium were identified
solely by blood cultures (Table 6 and 7).
Association between Mycobacterium avium infection and 
clinical data
The following factors (Table 6) were significantly associ-
ated with a culture positive for M. avium infections:
death during time of follow up (odds ratio [OR], 9.7 [95%
CI, 2.8–32]), loss of weight (OR, 8 [95% CI, 1.6–54]),
and diarrhea (OR, 3.9 [95% CI, 1.1–14]). The mean time
of survival during the study was significantly reduced in-
patients infected with Mycobacterium avium compared
to the ones not infected (154 ± 44 versus 170 ± 37 days, p
= 0.01). There were no statistically significant differenc-
es in age, sex, clinical stage, CD4 cell count, viral load,
use of antiretrovirals drugs or time of diagnosis since
HIV infection between patients with or without myco-
Table 2: Staining and culture of M. tuberculosis
Patient Clinical form Type of Sample Number of Samples AFB SMEAR POSITIVE CULTURE POSITIVE
1 Disseminated Sputum 2 2 2
Urine 2 0 2
Ascitic fluid 1 1 1
2* Pulmonary Sputum 2 2 2
Stool 2 2 2
3 Pulmonary Sputum 2 0 2
Stool 2 1 2
4 Gastrointestinal Stool 2 2 2
TOTAL 15 10 15
2* This patient also presented positive culture for M. avium
Table 3: Staining and culture of M. avium in blood samples
AFB smear Culture
Patient Sample Number of Samples Positive Negative Positive Negative
1 blood 2 1 1 2 0
2 blood 2 1 1 2 0
3 blood 2 1 1 2 0
3* blood 2 0 2 2 0
urine 2 1 1 2 0
stool 2 2 0 2 0
T O T A L 1 2 6 61 20
3* Sample after one month of follow. This patient had past history of tuberculosisBMC Infectious Diseases 2001, 1:21 http://www.biomedcentral.com/1471-2334/1/21
bacterial infection (Table 7). However, there were no pa-
tients with M. avium infections in clinical stage A or with
a CD4 cell count higher than 500 cells/mm3 (Tables 8
and 9).
Discussion
Our study was a prospective study in HIV infected pa-
tients in whom an indiscriminate search Mycobacterium
infection was done. Clinical suspicion of tuberculosis ex-
isted previous to enrollment only in the two patients with
pulmonary  Mycobacterium tuberculosis infection but
not in the other two patients with extrapulmonary tuber-
culosis.
Most of Mycobacterium species isolated were M. avium
The frequency that we found was lower than that of pre-
viously reported studies for Mycobacterium in HIV in-
Table 4: Staining and culture of M. avium in clinical samples other than blood
AFB Smear Culture
PATIENT SAMPLE Number of Samples POS NEG POS NEG
1 Stool 2 0 2 1 1
2 Stool 2 0 2 1 1
3 Stool 2 2 0 2 0
4U r i n e 2 0 2 2 0
5U r i n e 2 0 2 2 0
6U r i n e 2 0 2 1 1
7U r i n e 2 0 2 2 0
8* Sputum 2 2 0 2 0
9* Sputum 2 2 0 1 0
TOTAL 18 6 12 14 3
8* Patient with past history of TB 9* Patient with simultaneous finding of M. tuberculosis
Table 5: Positivity for Mycobacterium infection and type of sample (n = 1622)
SAMPLE CULTURE AFB Smear
POSITIVE NEGATIVE POSITIVE NEGATIVE
N%n % n% n %
Blood 8 1.2 640 98.8 3 0.5 645 99.5
Stool 12 3.2 362 96.8 11 3 363 97
Sputum 8 8 93 92 6 6 93 94
CSF 0 0 1 100 0 0 1 100
Ascitic fluid 1 100 0 0 1 100 0 0
TOTAL 40 2.5 1582 97.5 22 1.3 1600 98.7
Table 6: Clinical findings associated with Mycobacterium avium 
infection
Clinical findings Odds Risk CI 95% p
Death* 9.7 (2.8 – 32) 0.0005
Loss of weight* 8.0 (1.6 – 54) 0.004
Diarrhea* 4.5 (1.1 – 14) 0.017
Hemoptysis 3.6 (0 – 16) 0.1
Cough 2.1 (0.6 – 6.9) 0.2
Hospitalization 2.5 (0.7 – 8.3) 0.1
History of past TB 2.1 (0.4 – 7.9) 0.2
Dyspnea 1.9 (0.5 – 6.8) 0.2
Fever 1.7 (0.5 – 5.5) 0.3
Lymphadenopaties 1.0 (0.2 – 5.7) 1.0
* Statistically significant associations p < 0.05BMC Infectious Diseases 2001, 1:21 http://www.biomedcentral.com/1471-2334/1/21
fected patients in Colombia. A previous study at the
"Hospital San Juan de Dios" in 1996 performed in 92
HIV infected patients found a prevalence of 8% for M. tu-
berculosis infection [25]. In another study in 101 patients
in Cali, Colombia, the prevalence was only 2% [26]. In
the present study it was 1.4%.
The prevalence of non-tuberculous Mycobacterium spe-
cies in Cali was 5% [27], and in the current study it was
4%. The lower prevalence of M. tuberculosis, can be re-
lated to the introduction of highly active antiretroviral
therapy (HAART) that was practically absent in the pre-
vious study in Bogota in 1996 but that was being used to
treat 68% of the patients in the current study. Our results
are also different to the ones reported in a General Hos-
pital, AIDS reference center, in Rio de Janeiro, Brazil
[28] where mycobacteria were recovered from 20.6%
(313 of 1,517) of all patients, and M. tuberculosis was
identified in 94.2% (295/313), and non-tuberculous my-
cobacteria in 5.8% (18/313). Our results suggest that
when antiretroviral therapy is introduced the relative
frequency of M. tuberculosis infections is reduced and
the one of M. avium infections increases [28].
We found that Mycobacterium avium infection was re-
lated to symptomatic diarrhea and greater mortality as
has been reported previously [29]. Our study shows that
frequency of isolation of M. avium was greater in urine
and stool samples. This emphasizes the need to take mul-
tiple body fluid samples in order to enhance the opportu-
nity of isolation increasing the microbiologic diagnostic
sensitivity. Interestingly, we found that blood AFB
smears can be useful to rapidly confirm a clinical diagno-
sis of disseminated Mycobacterium avium infection.
In the present study there were no resistant strains of M.
tuberculosis found. In a previous survey in Colombia it
was found that M. tuberculosis isolates among new cases
in patients without HIV infection showed resistance in
9.5% (4 of 42) [30].
Table 7: Demographic and clinical characteristics in patients with and without Mycobacterium avium infection
Patients with M. avium infec-
tion
1st and 3rd quar-
tile
Patients without M. avium 
infection
1st and 3rd 
quartile
p
N (patients 
with data)
Median or 
percent
N (patients 
with data)
Median or 
percent
Age 13 33 [23–39] 273 35 [29–40] 0.2
Sex male 13 92% 273 88% 0.5
CD4 cell counts 13 115 [30–223] 219 164 [60–325] 0.2
Viral load 8 52,000 [5,967–227,941] 172 23,000 [746–147,131] 0.5
Use of antiretrovirals 13 61.5% 272 68.7% 0.8
Time with antiretroviral 
treatment (months)
10 29 [18–60] 175 22 [12–32] 0.2
Time with diagnosis of 
VIH infection (months)
10 18.5 [15–28] 175 27 [13–50] 0.2
Table 8: Clinical stage of HIV infection and positivity for Mycobac-
terium infection
CLINICAL STAGE POSITIVE TOTAL
A 0 (0%) 0/31 (0%)
B 3 (19%) 3/69 (4.4%)
C 13 (81%) 13/186 (7%)
TOTAL 16 (100%) 16/286 
(5.6%)
Table 9: Relation between CD4 cell count and infection with 
Mycobacterium
CD4+ cells POSITIVES TOTAL
(> 500/mm3) 0 (0%) 0/24 (0%)
(200–499/mm3) 6 (37%) 6/83 (7.2%)
(< 200/mm3) 8 (50%) 8/126 (6.3%)
ND 2 (13%) 2/53 (3.7%)
TOTAL 16 (100%) 16/262 (6.1%)BMC Infectious Diseases 2001, 1:21 http://www.biomedcentral.com/1471-2334/1/21
Conclusions
Our study found that 5% of HIV infected patients in Bo-
gota were infected with Mycobacteria and that M. Avi-
um was the predominant species. It becomes evident the
need to improve the preventive measures and prompt
treatment of this type of opportunistic infection in the
HIV infected individuals.
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